HAS3

HAS3 is a plasma membrane hyaluronan synthase that drives extracellular matrix and cell-surface hyaluronan (HA) production, displaying the highest catalytic efficiency among the HAS isoenzymes and synthesizing HA rapidly even at low UDP-sugar substrate concentrations (PMID:23303191, PMID:25795779). Its synthetic output is governed by trafficking: HAS3 cycles rapidly between the plasma membrane and endosomes, and surplus cytosolic UDP-GlcNAc—acting in part through O-GlcNAcylation of HAS3—suppresses its endocytosis and lysosomal turnover, retaining the enzyme at the cell surface to stimulate HA synthesis and HAS3 shedding in extracellular vesicles (PMID:26883802). This retrograde endocytic traffic is controlled by the Rab10 GTPase, which binds HAS3 in endosomes; loss of Rab10 retains HAS3 at the plasma membrane, enlarges the cell-surface HA coat, and impairs cell adhesion in an HA-dependent manner (PMID:24509846). HAS3 assembles into homomeric and HAS1/HAS2 heteromeric complexes via its N-terminal domain in both Golgi and plasma membrane, with HAS3 homomers being the most synthetically active (PMID:25795779), and ongoing HA synthesis maintains HAS3 within plasma membrane protrusions and dorsal ruffles (PMID:26162854, PMID:26448759). Functionally, HAS3-derived HA regulates extracellular space volume and neuronal excitability—Has3-knockout mice show reduced hippocampal extracellular space and seizure susceptibility (PMID:24790187)—and modulates epithelial junction formation and mitotic spindle orientation (PMID:22159845), cell adhesion, migration and proliferation through HA-receptor and ERK signaling (PMID:26222208), and intercellular communication via extracellular vesicles carrying HA and Indian Hedgehog that activate hedgehog signaling in recipient cells (PMID:31820036). HAS3 expression is controlled transcriptionally through Sp1-dependent promoter elements (PMID:25843802), retinoic acid receptor signaling (PMID:23748778), and FOSL1 (PMID:38402581), and post-transcriptionally by miR-10b and miR-29a (PMID:31948751).

1. 2013 High

   Established that HAS3 is distinguished from other HAS isoenzymes by its ability to synthesize HA efficiently at low substrate concentrations, defining it as a high-efficiency, substrate-sensitive synthase.

   Evidence Transfection of COS-1 cells with human HAS1-3, with UDP-sugar manipulation and HA secretion measurement

   PMID:23303191

   Open questions at the time

   • Does not resolve the structural basis of HAS3's higher substrate affinity
   • Performed in transfected COS-1 cells, not native tissue
2. 2011 Medium

   Showed that HAS3-driven HA accumulation disrupts epithelial organization, linking the enzyme to junction formation and mitotic spindle orientation.

   Evidence Stable GFP-HAS3 overexpression in MDCK cells, 3D cyst culture, junction and spindle imaging

   PMID:22159845

   Open questions at the time

   • Based on overexpression; endogenous contribution unclear
   • Mechanism linking HA coat to spindle orientation not defined
3. 2014 High

   Identified Rab10 as the GTPase controlling HAS3 endocytic recycling, establishing trafficking as a determinant of surface HA synthesis and HA-dependent adhesion.

   Evidence Reciprocal Co-IP from endosomal fractions, Rab10 siRNA/overexpression, live imaging, adhesion assay with hyaluronidase rescue

   PMID:24509846

   Open questions at the time

   • Direct vs indirect Rab10-HAS3 interaction not distinguished
   • Single lab
4. 2014 High

   Demonstrated in vivo that HAS3 is the major source of hippocampal HA and that its loss reduces extracellular space and provokes epileptiform activity, establishing a physiological role in brain tissue architecture and excitability.

   Evidence Has3-/- knockout mice with iontophoretic ECS measurement, diffusion imaging, slice electrophysiology, osmotic manipulation

   PMID:24790187

   Open questions at the time

   • Molecular link between ECS volume and neuronal excitability not fully resolved
   • Does not address HAS3 function outside the hippocampus
5. 2015 High

   Resolved HAS3 oligomerization, showing it forms homo- and heteromeric complexes with HAS1/HAS2 via its N-terminal domain, with functional consequences for HA output.

   Evidence FRET in live cells, proximity ligation assay on endogenous HAS, C-terminal deletion mapping

   PMID:25795779

   Open questions at the time

   • Stoichiometry of complexes unknown
   • No structural model of the assembly interface
6. 2015 Medium

   Established that ongoing HA synthesis physically retains HAS3 in plasma membrane protrusions and dorsal ruffles, coupling enzymatic activity to membrane morphology.

   Evidence GFP-HAS3 overexpression with hyaluronidase rescue, cytoskeletal marker immunostaining, and CLEM

   PMID:26162854 PMID:26448759

   Open questions at the time

   • Based on overexpression
   • Functional role of protrusion localization not defined
7. 2015 Medium

   Connected HAS3-driven HA coat expansion to suppression of melanoma adhesion, migration and proliferation through both HA-receptor-dependent and ERK-dependent routes.

   Evidence Inducible HAS3 expression in MV3 cells with hyaluronidase/oligosaccharide blocking, cell-cycle analysis, ERK1/2 western blot

   PMID:26222208

   Open questions at the time

   • Mechanism of receptor-independent proliferation arrest unresolved
   • Single cell line
8. 2015 Medium

   Defined the HAS3 core promoter architecture, identifying functional Sp1 sites and an MTE that drive transcription in the absence of a TATA box.

   Evidence 5' RACE, deletion analysis, site-directed mutagenesis of Sp1/MTE sites, luciferase reporters

   PMID:25843802

   Open questions at the time

   • Upstream signals converging on Sp1 not identified
   • Tissue specificity of promoter variants unknown
9. 2013 Medium

   Linked retinoic acid receptor signaling to HAS3 induction, showing carotenoid metabolites can upregulate HAS3 and HA synthesis in keratinocytes.

   Evidence RAR antagonist and retinal dehydrogenase inhibitor treatment, RARE reporter, qPCR in human keratinocytes

   PMID:23748778

   Open questions at the time

   • Direct RAR binding to the HAS3 locus not shown
   • Identity of active metabolite inferred
10. 2016 High

    Showed that cytosolic UDP-GlcNAc and O-GlcNAcylation control HAS3 surface residence by modulating endocytosis and lysosomal decay, coupling metabolic state to HA synthesis and vesicular shedding.

    Evidence Live-cell imaging, endocytosis assays, O-GlcNAc pharmacology, EV isolation in HAS3-expressing cells

    PMID:26883802

    Open questions at the time

    • O-GlcNAc modification site on HAS3 not mapped
    • Single lab
11. 2019 Medium

    Revealed that HAS3-loaded extracellular vesicles carry IHH and activate hedgehog signaling in recipient cells via CD44-HA binding, establishing HAS3 in intercellular signaling and pro-tumorigenic communication.

    Evidence GFP-HAS3 melanoma EV isolation, CD44 blocking, hedgehog reporter, c-Myc/claspin western blot, IHH proteomics

    PMID:31820036

    Open questions at the time

    • Mechanism of IHH loading into EVs unknown
    • Overexpression-based system
12. 2020 Medium

    Identified miR-10b and miR-29a as direct post-transcriptional repressors of HAS3, linking its regulation to prostate cancer neuroendocrine transdifferentiation.

    Evidence 3'UTR luciferase reporters, western blot, qRT-PCR, proliferation/migration assays in LNCaP cells

    PMID:31948751

    Open questions at the time

    • Context-dependent direction of HAS3's effect on proliferation/colony formation unresolved
    • Single cell line
13. 2022 Medium

    Placed HAS3 in airway progenitor fate decisions, showing its delayed upregulation promotes goblet cell differentiation during allergic inflammation.

    Evidence IL-4 stimulation of nasal epithelial cells, 4-methylumbelliferone inhibition, murine allergic rhinitis model, cell-type-resolved expression

    PMID:35679095

    Open questions at the time

    • 4-MU inhibits HA synthesis broadly, not HAS3-specifically
    • HAS3-specific genetic perturbation not performed
14. 2024 Medium

    Established FOSL1 as a transcriptional activator of HAS3 controlling HA-dependent cancer stem cell properties, identifying a druggable upstream regulator.

    Evidence FOSL1 knockdown/overexpression, HAS3 mRNA/protein, HA ELISA, sphere formation, in vivo tumor-initiating assays in HNSCC

    PMID:38402581

    Open questions at the time

    • Direct FOSL1 binding to HAS3 promoter only implied
    • Single tumor type

• The molecular basis of HAS3 substrate specificity, the precise O-GlcNAc modification sites controlling its trafficking, and the structural organization of its homo/heteromeric complexes remain unresolved.
• No structural model of HAS3 or its complexes
• O-GlcNAc and trafficking signal residues unmapped
• Direct vs indirect Rab10 interaction unresolved